Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/36—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
  • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D223/16—Benzazepines; Hydrogenated benzazepines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

• R O Y ⁇ 0 i L SOzNH-il-NH-R wherein R is straight or branched chain saturated or unsaturated aliphatic of up to 10 carbon atoms, monoor polycyclic cycloaliphatic and the corresponding ring systems wherein the carbon atom in the ring system of R at the point of linkage to the adjacent NH-group is replaced by a nitrogen atom, cycloalkylalkyl substituted by lower alkyl or polycycloalkylalkyl substituted by lower alkyl,
• R and R" are hydrogen, halogen, alkyl, phenyl, monoor di-halophenyl or lower alkoxyphenyl, or R and R" are alkyl linked together;
• X is oxygen, sulphur, nitrogen or nitrogen whose hydrogen atom is replaced by alkyl, aryl, aralkyl or by alkyl, aryl or aralkyl substituted by halogen, alkyl, alkoxy or trifluoromethyl, and
• Y and Z are unsubstituted or alkyl-substituted alkylene of 1 to 3 carbon atoms, or if Y or Z is at least 2 carbon atoms, the other one may be a direct bond, and pharmaceutically acceptable non-toxic salts thereof, exhibit blood sugar depressant properties and are thus useful agents in the treatment of diabetes.
• These compounds may be produced by the reaction of amino compounds with sulphonamide derivatives or arylsulphonyl isocyanates or by reacting sulphonamides with amine derivatives or isocyanate derivatives.
• N- (4- methyl-benzene-sulphonyl)-N'-butyl urea has achieved great importance as a therapeutical agent for the treatment of diabetes because of its blood sugar depressant activity and its good compatibility upon administration to humans.
• R is straight or branched chain saturated or unsaturated alkyl of up to 10 carbon atoms, i.e. alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms or alkynyl of 2 to 10 carbon atoms, a member selected from the group consisting of cycloalkyl, bicycloalkyl, tricycloalkyl, tetracycloalkyl, cycloalkyl substituted by alkyl of 1 to 4 carbon atoms, bicycloalkyl substituted by alkyl of l to 4 carbon atoms, tricycloalkyl substituted by alkyl of 1 to 4 carbon atoms, tetracycloalkyl substituted by alkyl of l to 4 carbon atoms and the corresponding ring systems wherein the carbon atom in the ring system of R at the point of linkage to the adjacent NH-group is replaced by a nitrogen atom
• R and R" are hydrogen, halogen, alkyl, alkyl linked to one another (that is, R and R may each be an alkyl group which alkyl groups are linked to one another), phenyl, monoor di-halophenyl or lower alkoxyphenyl,
• X is oxygen, sulphur, nitrogen or nitrogen whose hydrogen atom is substituted by alkyl, especially lower alkyl, aryl, aralkyl or alkyl, aryl or aralkyl substituted by a member selected from the group consisting of halogen, alkyl, especially lower alkyl, alkoxy, especially lower alkoxy and trifluoromethyl, and
• Y and Z are alkylene of 1 to 3 carbon atoms, alkylene of 1 to 3 carbon atoms substituted by alkyl of 1 to 4 carbon atoms or if Y or Z consists of at least 2 carbon atoms, the other one is a direct bond,
• alkali metal salts and alkaline earth metal salts are particularly useful and valuable forms of the present invention. These compounds, including the salts, exhibit a strong blood sugar depressant eliect which is superior to that exhibited by tolbutamide.
• the compounds of the present invention may be adminstered by the same general routes and in the same general or lower dosage ranges as known blood sugar depressant compounds such as tolbutamide, although it should be clearly borne in mind that variations in dosage range such as a lowering of the dosage range may be indicated and that such considerations as the severity of the condition, the past and present medical history of the patient, etc. must be taken into consideration in determining the precise dosage range.
• the compounds of the present invention are particularly suitable for oral administration.
• the compounds of the present invention may be prepared by procedures per se known. For example, amino compounds of the formula:
• the part of the molecule may be derived from the following compounds, for example:
• Suitable amino compounds on which the group NHR in the products of the present process is based are, for example:
• cycloalkylamines such as cyclopentylamine, 2-methyl-cyclopentylamine, cyclohexylamine, 3-methyl-cyclohexylamine, 4,4-dimethyl-cyclohexylamine, cycloheptylamine, cyclooctylamine, bicyclo-[2,2,1]-heptyl-2-amine, nortricyclylamine, adamantylamine, adamantylmethylamine, 2- methylbicyclo-[2,2,1]-heptyl-2-methylamine, oc- (bicyclo- [2,2,1]-heptyl 2) ethylarnine, fenchylamine, bornylamine, cyclohcxen-l-yl-ethylamine; furthermore, cyclic N-amino compounds such as l-amino
• the amines can be used as such or in the form of their derivatives such as carbamic acid chlorides, carbamic acid esters or carbamic acid azides.
• the compounds of the present invention which may contain one or more optically active carbon atoms can be obtained not only in the form of their racemates, but also in the form of their optically active isomers.
• optically active isomers these can be produced either by using a suitable optically active starting material or by subjecting either the racemic intermediates or the racemic final products to resolution by techniques which are per se known.
• Example 6 In the manner described in Example 1(0), there is obtained from indoline-6-sulphonamide and S-methyl-isoxazole-S-carboxylic acid chloride, the I-(S-methyl-isoxazole-3-carbonyl)indoline-6-sulphonamide in the form of colorless crystals of M.P. 198 C.; from this compound and cyclohexyl-isocyanate, the N[1-(5-methyl-isoxazole- 3 carbonyl)-indoline-6-sulphonyl]-N'-cyclohexyl-urea is obtained in analogy with Example 1(d) in the form of a colorless, finely crystalline powder; M.P. 197 C.
• EXAMPLE 7 (a) In a manner similar to that described in Example 1(a), l-acetyl-1,2,3,4-tetrahydro-quinoline is converted into 1 acetyl-1,2,3,4-tetrahydroisoquinoline-G-sulphonamide of M.P. 170-l71 C. by the reaction with chlorosulphonic acid and subsequent reaction aqueous ammonia.
• This compound can be reacted in analogy with Example 1(d) with cyclohexyl-isocyanate to form the corresponding N-[Z-(S-methyl-isoxazole-Bcarbonyl)- 8 1,2,3,4 tetrahydroisoquinoline-sulphonyl]-N'-cyclohexyl-urea of M.P. 163 C.
• the blood sugar depressing elfect of the new compounds was determined on intact, fed rats by oral application in the form of a suspension in tragacanth slime and measuring of the blood sugar level according to Hofimann, J. Biol. Chem. 120, 51 (1937).
• the figures are average values of six test animals per dose.
• mice The toxicity of these compounds is low. 2 g. per kg. body weight, administered per os, are tolerated by mice without any symptoms.
• the compounds of the present invention can be combined with suitable pharmaceutically acceptable inert diluents and carriers in accordance with techniques and procedures which are per se known in the pharmaceutical field.
• the compounds of the present invention may be combined with pharmaceutically acceptable non-toxic inert diluents or carriers to form pharmaceutical compositions which may be administered to humans and such compositions may be in any of the forms which are conventionally used including but not limited to tablets, capsules, solutions, suspensions, emulsions, sterile solutions and the like, namely forms which are suitable for administration to humans.
• R is a straight or branched chain alkyl of 1 to 10 carbon atoms, monocycloalkyl of to 8 carbon atoms, said monocycloalkyl being unsubstituted or substituted by lower alkyl of 1 to 4 carbon atoms, or monocyclic amino selected from the group consisting of pyrrolidino, piperidine and hexamethylene imino, said monocyclic amino being unsubstituted or substituted by lower alkyl of 1 to 4 carbon atoms, the nitrogen atom of said monocyclic amino being linked to the adjacent NH group
• R and R" are hydrogen, halogen, alkyl of 1 to 8 carbon atoms, phenyl, or monoor di-halophenyl
• Y and Z are alkylene of 1 to 3 carbon atoms, said alkylene being unsubstituted or substituted by lower alkyl of 1 to 4 carbon atoms, or one of Y or Z is a direct bond and

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=5732707

Family Applications (1)

Country Status (11)

Cited By (6)

Families Citing this family (1)

Family Cites Families (1)

• 1969
  • 1969-04-29 DE DE19691921737 patent/DE1921737A1/de active Pending
• 1970
  • 1970-03-30 IL IL7034203A patent/IL34203A/en unknown
  • 1970-04-01 CH CH480470A patent/CH537400A/de not_active IP Right Cessation
  • 1970-04-24 JP JP45034799A patent/JPS4945870B1/ja active Pending
  • 1970-04-27 CA CA081184A patent/CA934754A/en not_active Expired
  • 1970-04-27 US US00032465A patent/US3752818A/en not_active Expired - Lifetime
  • 1970-04-28 NL NL7006208A patent/NL7006208A/xx unknown
  • 1970-04-29 FR FR7015794A patent/FR2042389B1/fr not_active Expired
  • 1970-04-29 BE BE749742D patent/BE749742A/xx unknown
  • 1970-04-29 GB GB20667/70A patent/GB1244593A/en not_active Expired
  • 1970-04-29 AT AT390370A patent/AT297730B/de not_active IP Right Cessation
• 1974
  • 1974-07-08 JP JP49077464A patent/JPS5034030B1/ja active Pending

Also Published As

Similar Documents